Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib DDI with Itraconazole and Rifampin
NCT05255276Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Feb 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sitravatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoints: Maximum Plasma Concentration up to 168 hours, Area Under the Curve to Infinity up to 168 hours and 5 more. Started Feb 2022; status: completed.
02
Drugs
sitravatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05255276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05255276.